Have your own idea? Try our Stock Screener
U.S. Life Sciences Industry Analysis
UpdatedFeb 21, 2025
DataAggregated Company Financials
Companies65
- 7D0.9%
- 3M-4.6%
- 1Y-14.6%
- YTD-3.9%
Over the last 7 days, the Life Sciences industry has dropped 3.0%, driven by a pullback from West Pharmaceutical Services of 37%. The industry has fallen 14% in the last year. Earnings are forecast to grow by 16% annually.
Industry Valuation and Performance
Has the U.S. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 21 Feb 2025 | US$620.2b | US$143.3b | US$9.6b | 38.4x | 64.4x | 4.3x |
| Sun, 19 Jan 2025 | US$681.4b | US$142.4b | US$10.2b | 43.8x | 66.8x | 4.8x |
| Tue, 17 Dec 2024 | US$666.2b | US$142.4b | US$10.2b | 45.5x | 65.2x | 4.7x |
| Thu, 14 Nov 2024 | US$683.4b | US$142.4b | US$10.3b | 45x | 66.4x | 4.8x |
| Sat, 12 Oct 2024 | US$724.1b | US$141.8b | US$8.5b | 37.7x | 85.3x | 5.1x |
| Mon, 09 Sep 2024 | US$731.3b | US$141.8b | US$8.5b | 37.5x | 86.1x | 5.2x |
| Wed, 07 Aug 2024 | US$722.7b | US$141.0b | US$11.3b | 36.7x | 64.2x | 5.1x |
| Fri, 05 Jul 2024 | US$662.1b | US$141.3b | US$12.2b | 38.5x | 54.4x | 4.7x |
| Sun, 02 Jun 2024 | US$702.1b | US$141.3b | US$12.4b | 38.2x | 56.5x | 5x |
| Tue, 30 Apr 2024 | US$709.6b | US$141.6b | US$12.7b | 39.6x | 55.8x | 5x |
| Thu, 28 Mar 2024 | US$742.5b | US$142.1b | US$12.8b | 43.9x | 58x | 5.2x |
| Sat, 24 Feb 2024 | US$729.7b | US$142.1b | US$12.4b | 43.7x | 58.8x | 5.1x |
| Mon, 22 Jan 2024 | US$691.1b | US$153.8b | US$14.2b | 35.9x | 48.8x | 4.5x |
| Wed, 20 Dec 2023 | US$697.4b | US$153.8b | US$14.2b | 37.4x | 49x | 4.5x |
| Fri, 17 Nov 2023 | US$614.3b | US$153.9b | US$13.9b | 33.5x | 44.2x | 4x |
| Sun, 15 Oct 2023 | US$629.3b | US$154.6b | US$11.2b | 33.2x | 56.2x | 4.1x |
| Tue, 12 Sep 2023 | US$690.0b | US$154.6b | US$11.2b | 32.2x | 61.6x | 4.5x |
| Thu, 10 Aug 2023 | US$729.3b | US$154.6b | US$11.3b | 30.2x | 64.6x | 4.7x |
| Sat, 08 Jul 2023 | US$685.3b | US$152.4b | US$12.5b | 29.6x | 54.8x | 4.5x |
| Mon, 05 Jun 2023 | US$683.1b | US$152.4b | US$12.5b | 29.1x | 54.6x | 4.5x |
| Wed, 03 May 2023 | US$696.7b | US$152.9b | US$9.4b | 28.7x | 73.9x | 4.6x |
| Fri, 31 Mar 2023 | US$715.3b | US$154.5b | US$10.8b | 26.5x | 66.3x | 4.6x |
| Sun, 26 Feb 2023 | US$712.1b | US$154.3b | US$11.0b | 30.1x | 65x | 4.6x |
| Tue, 24 Jan 2023 | US$784.3b | US$155.3b | US$8.5b | 31.9x | 92x | 5x |
| Thu, 22 Dec 2022 | US$747.2b | US$155.2b | US$8.8b | 28.7x | 85.1x | 4.8x |
| Sat, 19 Nov 2022 | US$749.5b | US$154.9b | US$8.8b | 27.8x | 84.7x | 4.8x |
| Mon, 17 Oct 2022 | US$693.0b | US$152.5b | US$17.0b | 23.6x | 40.7x | 4.5x |
| Wed, 14 Sep 2022 | US$811.0b | US$152.3b | US$17.3b | 30.9x | 46.8x | 5.3x |
| Fri, 12 Aug 2022 | US$836.9b | US$152.1b | US$18.0b | 33.5x | 46.6x | 5.5x |
| Sun, 10 Jul 2022 | US$747.5b | US$148.1b | US$20.1b | 31.1x | 37.2x | 5x |
| Tue, 07 Jun 2022 | US$752.3b | US$148.1b | US$20.1b | 31.4x | 37.4x | 5.1x |
| Thu, 05 May 2022 | US$779.7b | US$151.0b | US$20.9b | 33.9x | 37.3x | 5.2x |
| Sat, 02 Apr 2022 | US$878.5b | US$146.0b | US$25.4b | 37x | 34.6x | 6x |
| Mon, 28 Feb 2022 | US$854.0b | US$146.1b | US$25.3b | 38.5x | 33.8x | 5.8x |
Price to Earnings Ratio
33.8x
Current Industry PE
- Investors are optimistic on the American Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 62.0x which is higher than its 3-year average PE of 58.8x.
- The 3-year average PS ratio of 4.8x is higher than the industry's current PS ratio of 4.3x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 27% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.41% | |
| Healthcare | 0.18% | |
| Life Sciences | 0.93% | |
| Clinical Research and Equipment | 0.93% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| DHR Danaher | US$207.95 | 2.1% +US$3.1b | -17.7% | PE38.4x | |
| TMO Thermo Fisher Scientific | US$537.83 | 1.0% +US$2.0b | -4.0% | PE32.5x | |
| ICLR ICON | US$201.84 | 10.5% +US$1.6b | -35.6% | PE21.1x | |
| RGEN Repligen | US$162.67 | 11.3% +US$924.4m | -15.9% | PS14.4x | |
| CRL Charles River Laboratories International | US$162.25 | 5.9% +US$464.3m | -34.3% | PE805.8x |
